Premier Research conducted pivotal Phase 3 studies to evaluate the efficacy and safety of a compound to treat adult Binge Eating Disorder (BED). Patients enrolled quickly due to a significant unmet need for an effective pharmacologic treatment. With unexpectedly fast enrollment, primarily in the U.S., the European arm of the study was downsized. The team expanded staffing, doubling the number of CRAs to 45 and assigning 10 clinical managers. Effective collaboration with the central laboratory, data manager, and other participants enabled the delivery of conclusive and positive results eight months ahead of the original 19-month schedule.

Join for free to read